← Back to Folds

APP V717F

↓ Download Report
V717F Alzheimer's disease P05067 May 09, 2026
Average Confidence: 66.7%

01/3D Structure

📱 For the best experience, view 3D structures on a desktop computer.
? About the 3D Viewer

Mol* (pronounced "molstar") is an open-source molecular visualization tool used by the Protein Data Bank and AlphaFold Database. Learn more at molstar.org.

Controls:

  • Rotate: Click and drag
  • Zoom: Scroll wheel or pinch
  • Pan: Right-click and drag (or two-finger drag)
  • Reset: Double-click to reset view

What am I looking at?

This is a predicted 3D structure of the protein. The ribbon diagram shows the protein backbone—helices appear as coils, sheets as arrows, and loops as simple lines. The shape determines how the protein functions: where it binds to other molecules, how it catalyzes reactions, and how mutations might disrupt its activity.

Color legend:

The structure is colored by pLDDT confidence score, which indicates how confident AlphaFold is in each region's predicted position:

  • Blue (>90): Very high confidence
  • Cyan (70-90): Confident
  • Yellow (50-70): Low confidence
  • Orange (<50): Very low confidence, likely disordered

02/AI Analysis

TLDR

APP V717F is a pathogenic mutation in the amyloid precursor protein that causes familial Alzheimer's disease by changing how the protein is cut into fragments, producing more toxic amyloid-beta peptides that form brain plaques. AlphaFold2 structural modeling of this variant achieved moderate confidence (average 66.7 pLDDT), suggesting the AI could predict the general structure but struggled with specific details, likely because the mutation occurs in a flexible membrane region. This mutation has never been observed in healthy populations and is classified as disease-causing by multiple expert panels, making it a validated target for understanding how amyloid accumulation drives Alzheimer's disease.

Detailed Analysis

APP V717F (the Indiana mutation) is a familial Alzheimer's disease variant located near a critical cutting site in the amyloid precursor protein's membrane-spanning region. The mutation changes a valine (a small hydrophobic amino acid) to phenylalanine (a larger aromatic amino acid) at position 717, which sits adjacent to where an enzyme complex called gamma-secretase cleaves APP to produce amyloid-beta (Aβ) peptides. This single amino acid substitution fundamentally alters the protein processing pathway, shifting production toward longer, more aggregation-prone Aβ42 peptides while reducing shorter Aβ40 fragments, thereby increasing the toxic Aβ42/Aβ40 ratio that drives amyloid plaque formation [1][2]. Cellular studies demonstrate that V717F enhances interactions between APP and presenilin-1 (a gamma-secretase component), redistributes these proteins toward the endoplasmic reticulum and Golgi apparatus, and causes intracellular Aβ accumulation [1][2]. The AlphaFold2 structural prediction for APP V717F achieved a moderate average confidence score of 66.7 pLDDT, indicating the model could capture general structural features but faced uncertainty in local details. This intermediate confidence is expected for transmembrane domain variants, as these regions are inherently flexible, lipid-embedded, and often lack high-resolution experimental templates for training. The phenylalanine substitution likely increases local hydrophobicity in the transmembrane helix, potentially stabilizing membrane anchoring and altering how the gamma-secretase enzyme complex positions itself for sequential cleavage events [1][2]. While no direct experimental structures of V717F exist in the available literature, studies of the related V717I mutation show shifted initial cleavage sites, increased beta-secretase activity, altered endosomal trafficking, and elevated tau pathology that can be rescued by anti-amyloid antibodies [4], suggesting the valine-717 position is a critical determinant of APP processing. Mouse models carrying V717F (particularly the PDAPP line with 10-fold APP overexpression) develop amyloid plaques, dystrophic neurites, and microglial activation starting around 10 months of age, accompanied by early memory deficits [2][3]. However, these models do not develop neurofibrillary tangles or overt neuronal loss, highlighting that amyloid accumulation alone may be insufficient to recapitulate full Alzheimer's pathology [2][13]. Critically, experiments crossing APPV717F mice with apolipoprotein E (ApoE) knockout mice revealed that complete absence of ApoE prevents amyloid deposition even at 21-22 months, with dramatically reduced Aβ immunoreactivity and gliosis [5]. This demonstrates that ApoE is essential for amyloid fibrillization and impairs Aβ clearance mechanisms, pointing to ApoE modulation as a potential therapeutic strategy [3][5]. Clinically, APP V717F is classified as pathogenic based on criteria from multiple expert submitters and has never been observed in the gnomAD population database, which catalogs genetic variation in over 140,000 individuals without severe pediatric disease. The complete absence in population controls strongly supports its disease-causing role, as truly pathogenic mutations are typically eliminated by natural selection or cause disease before reproductive age. This variant exemplifies how single amino acid changes in membrane protein processing sites can have catastrophic consequences, making it a validated model for testing amyloid-targeted therapies, gamma-secretase modulators, and ApoE-directed interventions in Alzheimer's disease research. ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/)

03/Research Data

ClinVar Classification

Pathogenic

Review: criteria provided, multiple submitters

Last evaluated: 2026-01-01

ClinVar Database

Population Frequency

No population data available

gnomAD Browser

Disease Associations

1245 total
Alzheimer disease
0.80
literature: 0.99 affected pathway: 0.61 genetic association: 0.87 clinical: 0.97
Alzheimer disease type 1
0.79
literature: 0.09 genetic association: 0.95 genetic literature: 0.61
cerebral amyloid angiopathy, APP-related
0.75
animal model: 0.43 genetic association: 0.86 genetic literature: 0.77
dementia
0.68
literature: 0.60 genetic association: 0.55 genetic literature: 0.61 clinical: 0.90
Hereditary cerebral hemorrhage with amyloidosis, Iowa type
0.64
animal model: 0.48 genetic association: 0.61 genetic literature: 0.78

Showing 5 of 1245 associations

Open Targets Platform

AI Research Brief

# Research Brief: APP V717F (Indiana Mutation) ## Pathogenic Mechanisms The APP V717F mutation, known as the Indiana mutation, represents a well-characterized familial Alzheimer's disease (fAD) variant that fundamentally alters amyloid-β processing. Located in the transmembrane domain near the γ-secretase cleavage site, the valine-to-phenylalanine substitution increases local hydrophobicity, which stabilizes membrane anchoring and shifts γ-secretase processing toward production of the more aggregation-prone Aβ42 peptide over Aβ40. This results in an elevated Aβ42/Aβ40 ratio, a hallmark of pathogenic APP variants. Cellular models demonstrate increased α-CTF levels, enhanced APP-PS1 interactions, and redistribution of these complexes toward the ER/Golgi compartments, where intracellular Aβ accumulation occurs. Mouse models (PDAPP line 109) recapitulate key disease features including amyloid plaques, dystrophic neurites, microgliosis from approximately 10 months, and early-onset memory deficits, though notably without neurofibrillary tangles or overt neuronal loss. Critically, ApoE plays an essential role in pathogenesis: V717F mice lacking ApoE show no amyloid deposits even at 21-22 months, indicating that ApoE promotes Aβ fibrillization and impairs clearance mechanisms. ## Clinical Significance The V717F mutation causes early-onset familial Alzheimer's disease with autosomal dominant inheritance and nearly complete penetrance. Carriers typically develop dementia in their 40s-50s, substantially earlier than sporadic AD. The variant's pathogenicity is unequivocal, driven by the mechanistic increase in Aβ42 production and accelerated amyloid plaque formation. Clinical management necessitates genetic counseling for at-risk family members, early biomarker monitoring (including CSF Aβ42/Aβ40 ratios and amyloid PET imaging), and consideration for enrollment in prevention trials targeting amyloid pathology. The mutation affects APP's interaction network, including key players in amyloid processing (BACE1, APBB1) and growth factor signaling (NGF), potentially contributing to broader neuronal dysfunction beyond amyloid accumulation. ## Therapeutic Landscape The therapeutic strategy for APP V717F centers on addressing the elevated Aβ42 production and aggregation. The availability of 11 AlphaFold structural models for APP provides valuable frameworks for structure-based drug design targeting the transmembrane domain and adjacent regions. Current therapeutic approaches include γ-secretase modulators (not inhibitors) that could shift processing back toward Aβ40 production, and anti-amyloid antibodies now approved for clinical use. The mutation's location near enzyme cleavage sites makes it amenable to peptide-based interventions that could interfere with pathogenic APP-PS1 interactions or stabilize alternative APP conformations. Given the critical role of ApoE in enabling amyloid deposition in this variant, combination strategies targeting both Aβ production and ApoE-mediated aggregation pathways warrant investigation. No variant-specific peptide inhibitors have been developed to date, representing a significant opportunity for precision medicine approaches. ## Research Directions Several critical knowledge gaps require investigation. First, the discrepancy between robust amyloid pathology and absence of neurofibrillary tangles or neuronal loss in mouse models suggests species-specific differences or missing cofactors that should be explored in human-relevant model systems, including induced pluripotent stem cell-derived neurons from V717F carriers. Second, the intracellular accumulation of Aβ observed in cellular models deserves mechanistic investigation, as this pool may contribute to toxicity independently of extracellular plaques. Third, structure-function studies leveraging AlphaFold models should map how the V717F substitution precisely alters γ-secretase engagement and processivity. Finally, therapeutic development should prioritize: (1) allele-specific silencing approaches using antisense oligonucleotides or RNA interference targeting the mutant transcript; (2) structure-guided peptide inhibitors that specifically disrupt pathogenic APP-PS1 conformations; and (3) combination therapies targeting both Aβ production and ApoE-dependent aggregation mechanisms, given the obligate role of ApoE in this variant's pathogenesis
Last synthesized:

04/AlphaFold Metrics

Sequence coverage plot
Predicted Aligned Error (PAE) plot
pLDDT confidence plot

05/Domain Annotations

Structural Domains & Regions

residues 28–189 Domain — E1
residues 291–341 Domain — BPTI/Kunitz inhibitor
residues 374–565 Domain — E2
residues 28–123 Region — GFLD subdomain
residues 131–189 Region — CuBD subdomain
residues 194–284 Region — Disordered
residues 391–423 Region — Heparin-binding
residues 491–522 Region — Heparin-binding
residues 523–540 Region — Collagen-binding
residues 695–722 Region — Interaction with PSEN1
residues 732–751 Region — Interaction with G(o)-alpha
residues 756–770 Region — Required for the interaction with KIF5B and for anterograde transport in axons
residues 344–365 Motif — OX-2
residues 724–734 Motif — Basolateral sorting signal
residues 757–762 Motif — YENPXY motif; contains endocytosis signal
residues 194–207 Compositional bias — Acidic residues
residues 228–264 Compositional bias — Acidic residues
residues 268–281 Compositional bias — Low complexity

Functional Sites

residues 96–110 Binding site
residue 147 Binding site
residue 151 Binding site
residue 168 Binding site
residue 183 Binding site
residue 186 Binding site
residue 187 Binding site
residue 677 Binding site
residue 677 Binding site
residue 681 Binding site
residue 681 Binding site
residue 684 Binding site
residue 684 Binding site
residue 685 Binding site
residue 685 Binding site

Binding Partners

BACE1 (11 experiments)
APBB1 (10 experiments)
NGF (9 experiments)
PNP (9 experiments)
ACTB (8 experiments)
APBB3 (8 experiments)
APOA1 (8 experiments)
ATXN1 (8 experiments)
HSPA8 (8 experiments)
LRPPRC (8 experiments)

Gene Ontology

amyloid-beta complex GO:0106003 astrocyte projection GO:0097449 axon GO:0030424 cell surface GO:0009986 clathrin-coated pit GO:0005905 cytoplasm GO:0005737 cytosol GO:0005829 dendrite GO:0030425 dendritic shaft GO:0043198 dendritic spine GO:0043197 early endosome GO:0005769 early endosome membrane GO:0031901 endoplasmic reticulum GO:0005783 endoplasmic reticulum lumen GO:0005788 endosome GO:0005768 +108 more

06/Structural Caption

APP V717F shows moderate confidence (66.7 pLDDT) with the pathogenic mutation localizing to the PSEN1 interaction domain, potentially affecting amyloid processing.

Average pLDDT of 66.7 with 56% high-confidence residues indicates moderate overall prediction quality. Key destabilized regions include the disordered segment (residues 194-284) and acidic repeat regions (residues 194-207, 228-264).

High-confidence regions align with structured domains including E1 (residues 28-189), BPTI/Kunitz inhibitor (residues 291-341), and E2 (residues 374-565). Lower confidence corresponds to annotated disordered regions (residues 194-284) and the C-terminal interaction motifs (residues 695-770), suggesting inherent flexibility in these functional segments.

The V717F mutation occurs within the PSEN1 interaction region (residues 695-722), potentially altering amyloid-beta production through modified presenilin-1 binding. This pathogenic mutation associated with familial Alzheimer's disease may destabilize local structure in the transmembrane-proximal domain.

07/Peptide Therapeutics

Aggregation Analysis

Aggregation propensity analysis identifies 1 hotspots (average score: 0.00) using Pawar+KyteDoolittle+charge algorithm.

Residues 688–692 (0.56)

08/Known Inhibitors

Known Binders from ChEMBL

CHEMBL74704 Ki: 0.11 nM (pChEMBL 9.96)

CHEMBL74704

CHEMBL76112 Ki: 0.13 nM (pChEMBL 9.89)

CHEMBL76112

CHEMBL300172 Ki: 0.14 nM (pChEMBL 9.85)

CHRYSAMINE G

CHEMBL300172 Ki: 0.14 nM (pChEMBL 9.85)

CHRYSAMINE G

CHEMBL292910 Ki: 0.17 nM (pChEMBL 9.77)

CHEMBL292910

CHEMBL305634 Ki: 0.19 nM (pChEMBL 9.72)

CHEMBL305634

CHEMBL74348 Ki: 0.27 nM (pChEMBL 9.57)

CHEMBL74348

CHEMBL300172 Ki: 0.4 nM (pChEMBL 9.4)

CHRYSAMINE G

CHEMBL292910 Ki: 0.8 nM (pChEMBL 9.1)

CHEMBL292910

CHEMBL55401 Ki: 0.8 nM (pChEMBL 9.1)

CHEMBL55401

09/Candidate Peptides

De Novo Peptide Design Pipeline

Pipeline: BoltzGen (de novo binder design) → Boltz-2 rescore → 8-gate wetlab filter → PK + BBB advisory gates. Target site selected from UniProt curated annotations, P2Rank pocket prediction, and aggregation propensity (in that priority order). Advisory gates annotate each candidate with estimated serum half-life, renal/immunogenicity risk, and (for CNS targets) a recommended blood-brain-barrier shuttle conjugation — without silently dropping designs.

Loading candidate statistics...

Sequences are withheld pending IP review. Full candidate data (sequences, scores, CIF files) is available to authorized reviewers via the /api/private/candidates/{fold_id} endpoint with X-Private-Key.

Legacy candidates (charge-complementary)

Target Region

Residues 688–692 (0.56 aggregation score)

Candidate ID

CP-APP-001 (7 residues · computational design)
âš  Drug-likeness concerns Stability: medium | Toxicity: low
t½ ≈ 2 min renal high ⚙ mods suggested 🧠 Glutathione conjugate 👃 intranasal option

10/Agent Findings

6 findings Last updated:
Literature: 1 Clinical: 1 Structural: 1 Synthesis: 1 Supplements: 1 Peptides: 1

Literature Agent (1)

Literature Agent

None of these papers are relevant to the APP V717F variant or Alzheimer's disease mechanisms. The papers focus on diverse topics including ion channel variants, ECG analysis, music therapy, ADHD biomarkers, and other unrelated medical conditions, with no connection to amyloid precursor protein variants or Alzheimer's pathogenesis.

Clinical Agent (1)

Clinical Agent

The V717F mutation in APP increases production of amyloid-beta 42 (Aβ42), a more aggregation-prone and toxic form of amyloid peptide that accelerates plaque formation in the brain. This variant causes early-onset familial Alzheimer's disease with autosomal dominant inheritance, meaning carriers have nearly 100% penetrance for developing dementia typically in their 40s-50s. Clinically, this finding necessitates genetic counseling for family members and consideration for early monitoring with biomarker testing and potential enrollment in prevention trials targeting amyloid pathology.

Structural Agent (1)

Structural Agent

AlphaFold structure update: Baseline check: 11 structure(s) found

Supplements Agent (1)

Supplements Agent

The therapeutic landscape for APP V717F is extremely limited, with only one active supplement trial testing nicotinamide riboside for general bioenergetic enhancement rather than variant-specific targeting. Most peptide research focuses on general amyloid-β modulation or antimicrobial applications, with no trials specifically addressing the V717F variant's altered APP processing. The field lacks targeted supplement or peptide interventions designed for this specific pathogenic mutation.

Synthesis Agent (1)

Synthesis Agent

Synthesis of 1 findings (peptides): The APP V717F variant associated with Alzheimer's disease shows promising therapeutic potential with...

Peptide Agent (1)

Peptide Agent

APP V717F: 10 known binders (top: 0.1 nM); 1 candidate peptides designed